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Background: Generally, the results of high throughput analyses contain information about gene expressions, and
about exon expressions. Approximately 90% of primary protein-coding transcripts undergo alternative splicing in
mammals. However, changes induced by alternative exons have not been properly analyzed for their impact on
important molecular networks or their biological events. Even when alternative exons are identified, they are usually
subjected to bioinformatics analysis in the same way as the gene ignoring the possibility of functionality change
because of the alteration of domain caused by alternative exon. Here, we reveal an effective computational
approach to explore an important molecular network based on potential changes of functionality induced by
alternative exons obtained from our comprehensive analysis of neuronal cell differentiation.
Results: From our previously identified 262 differentially alternatively spliced exons during neuronal cell
differentiations, we extracted 241 sets that changed the amino acid sequences between the alternatively spliced
sequences. Conserved domain searches indicated that annotated domain(s) were changed in 128 sets. We obtained
49 genes whose terms overlapped between domain description and gene annotation. Thus, these 49 genes have
alternatively differentially spliced in exons that affect their main functions. We performed pathway analysis using
these 49 genes and identified the EGFR (epidermal growth factor receptor) and mTOR (mammalian target of
rapamycin) signaling pathway as being involved frequently. Recent studies reported that the mTOR pathway is
associated with neuronal cell differentiation, vindicating that our approach extracted an important molecular
network successfully.
Conclusions: Effective informatics approaches for exons should be more complex than those for genes, because
changes in alternative exons affect protein functions via alterations of amino acid sequences and functional
domains. Our method extracted alterations of functional domains and identified key alternative splicing events. We
identified the EGFR and mTOR signaling pathway as the most affected pathway. The mTOR pathway is important
for neuronal differentiation, suggesting that this in silico extraction of alternative splicing networks is useful. This
preliminary analysis indicated that automated analysis of the effects of alternative splicing would provide a rich
source of biologically relevant information.
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Approximately 23,000 human protein coding genes have
been identified; however, this is a much smaller number
than the expected over 200,000 human proteins [1]. Alter-
native splicing changes the use of exons, producing
multiple transcripts from a single gene, and enhances
proteomic diversity to support complexity in higher eu-
karyotes [2]. Indeed, it was reported that approximately
90% of human genes undergo alternative splicing [3].
There are five basic models of alternative splicing: exon
skipping, mutually exclusive type, 5’ splice site selection, 3’
splice site selection, and intron retention. Additionally,
alternative promoters and alternative polyadenylation sites
can produce alternative isoforms of transcripts. These
exons are sometimes continuously located on the genome,
resulting in complex alternative splicing [4].
According to physiological or environmental changes,
some alternative splicing occurs in a spatiotemporal man-
ner, regulated by alternative splicing regulators. Several
regulators, such as Nova1, RBFox1 and nPTB, and their
targets, have been identified in neural tissues and cells
[5-7]. Many isoforms produced by alternative splicing
have distinctly different functions, and play important bio-
logical roles [8,9]. Therefore, it is important to determine
critical alternative splicing networks based on biological
phenomena.
Over the last decade, many high throughput analyses
have been performed, and their information has accu-
mulated in databases. Both gene level expression and
exon level expression are available from analyses using
large-scale sequencing technologies. Furthermore, recently
developed standard microarrays may provide information
on both gene and exon expressions [10]. Certain differen-
tially expressed genes significantly affect biological phe-
nomena or are useful as molecular markers; therefore,
information on gene level expressions is generally well
analyzed. Moreover, critical gene networks or target genes
can be identified from gene expression information. How-
ever, this is not the case for exons.
Complicated species of alternative isoforms with small
numbers of nucleotide changes can be predicted compared
with genes. Thus, the quantitative credibility of an exon’s
information is generally much less than that of genes.
Moreover, the analysis of exons is more complex than that
of genes. Although some differentially alternatively spliced
exons have been investigated and extracted, the annotated
genes of these exons may be used to examine the critical
networks or targets [11-13]. However, significant changes
resulting from alternative exons may occur in protein do-
main(s). Advanced molecular dynamics techniques were
also applied to investigate alternative isoforms of parti-
cular individual isoforms [14-18]. These methods are not
currently applicable to the genome-wide investigation of
alternative isoforms at a time. Of course, several specializedprograms support informatics analyses of alternative exons
[19-22]. However, these do not support analyses of the pro-
tein domains encoded on alternative exons. In the case of
individual small-scale analysis, researchers generally check
alterations of amino acid sequences and of functional pro-
tein domains according to usages of alternative exons.
AltAnalyze and DomainGraph could provide protein
domain information from alternative exons although this
type of analysis of exons has been rarely applied compre-
hensively [23].
Previously, we analyzed comprehensively the differen-
tially alternatively spliced exons during neuronal differen-
tiation of P19 mouse embryonic carcinoma cells [12].
Validation by reverse-transcription polymerase chain reac-
tion (RT-PCR) suggested that 87% of the obtained 262
exons were differentially alternatively spliced in neuronal
cells compared with undifferentiated cells. Moreover, many
of the genes that were annotated by 262 exons were sug-
gested to be involved in neural events. Thus, the 262 exons
were plausible as neural splicing exons, and we considered
that these exons could be a good example group to investi-
gate alterative splicing networks.
In this article, we searched for a network that involved
these alternative splicing events using functional domain
information. Although individual studies have focused
on the functionalities of alternative spliced domains, all
comprehensively obtained exons were used as objects in
the domain functionality search. Ultimately, we identified
the EGFR (epidermal growth factor receptor) and mTOR
(mammalian target of rapamycin) signaling pathway as
the molecular network most associated with neural alter-
native splicing. The EGFR/mTOR pathway is an import-
ant cellular signaling pathway that controls cell growth
and proliferation [16,24]. This pathway has been inten-
sively studied, and many of the proteins involved have
been identified. Recently, studies have found that the
mTOR pathway plays important roles in the maintenance
of neural stem cells and the differentiation of neuronal
cells [reviewed in 25]. However, the relationship between
the EGFR/mTOR pathway and alternative splicing remains
unknown. Our investigation suggested that gene expres-
sion and exon expression of the transcripts involved in this
pathway were dramatically changed during neural differen-
tiation of P19 cells. Indeed, our trial showed that searching
for molecular network according to the functionalities of
alternatively spliced domains was an effective strategy.
Thus, it will help to precisely analyze mega data that are
available from comprehensive analyses.
Methods
Data set of the exon array during neuronal differentiation
of P19 cells
The accession number of the exon Array data is
GSE23710, which we analyzed and reported previously
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sequences, is available in the supplemental table of that
report [12], as is the information on the differentially
expressed genes.
Collection of annotated sequence data from the probeset
sequences
All probeset sequences were analyzed in the UCSC Blast-
like alignment (blat) search tool (http://genome.ucsc.edu/
cgi-bin/hgBlat) [26], and we determined alternative exons
or region sequences compared with the annotated Refseq
sequence, mRNA sequence or EST sequences. Similarly,
we manually selected the most typical and representative
sequences in which the alternative exon (or region) was
either joined to or excised from a transcript. All transcript
sequences were translated into amino acid sequences
using the ExPASy translate tool (Swiss Institute of Bio-
informatics). Sequences of the determined DAS exons
were also translated into amino acid sequences. Whole
amino acid sequences, excluding or including alternative
exons or regions, were compared and validated in the
UCSC blat search.
Conserved domain search for alternatively spliced isoforms
The obtained amino acid sequences were analyzed in the
NCBI conserved domain search [27], and alternatively
spliced domains were determined. Additionally, text de-
scriptions of these domains were retrieved.
Gene ontology analysis, pathway analysis and text mining
The GO analyses were performed for 128 DAS genes with
altered domain(s) [28]. The GO term(s) were compared
with the text descriptions of the domain(s). Overlaps
between GO terms and domain descriptions were found
in 49 out of 128 genes. These 49 genes were subjected to
pathway analysis and statistically-significant (Fisher’s Exact
Test p ≤ 0.01) biological process terms were obtained
using PathwayStudio® (Ariadne Genomics Inc., Rockville,
MD, USA) [28,29]. Although the schematic representation
of pathway analysis was based on this analysis, their rela-
tionships were validated by KEGG pathway analysis
(www.genome.jp/kegg/pathway.html) and by previous ar-
ticles for Arap1, Ep400 and Arhgef12 [30-32].
Cell culture and RNA purification
P19 cells were maintained in α minimum essential
medium (α-MEM; Sigma–Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum (FBS; Sigma–
Aldrich) [33]. To induce neuronal cell differentiation, P19
cells (1 × 105 cells/mL) were treated with 1 μM all trans-
retinoic acid at 4°C in a 10 cm petri dish (Falcon) with
α-MEM containing 10% FBS, as described previously
[33,34]. Total RNAs were collected from undifferentiated
cells (Day 0), cells during neuronal induction (Day 1–4),differentiation (Day 5–9), and from cells in the early glial
stage (Day 10–12) using the Trizol reagent (Life Technolo-
gies, Grand Island, NY, USA).
Semi-quantitative RT-PCR
The total RNAs of P19 cells were prepared as described
above. The cDNAs were produced from 2 μg of total
RNAs using SuperScript III (Life technologies) and 0.5 μg
of oligo dT primer in a 20 μL reaction mixture. The
cDNAs are used as templates for PCR. GoTaq polymerase
(Promega, Fitchburg, WI, USA) with specific primers per-
formed the PCR reactions. The DNA primer sequences,
number of cycles and annealing temperatures for the can-
didates are described in Additional file 1: Table S1. Primers
and conditions for β-Actin and GluR1 (controls) were de-
scribed in a previous report [34]. The PCR products were
analyzed on a 6% polyacrylamide gel. The gels were stained
with SYBR Green I (Takara Bio Inc., Otsu, Japan), and a
LAS-3000 (GE Healthcare, Fairfield, CT, USA) was used to
analyze the images. The sequences of the PCR products
were confirmed in a 3100 DNA sequencer (Life technolo-
gies). MultiGauge v 3.0 software (GE Healthcare) was used
to perform the densitometry. Each experiment was perfor-
med at least three times to confirm reproducibility.
As for Ethics, this research did not involve any human
subject, human material, or human data, and was not
performed on any animals. This research involved Recom-
binant DNA Experiments and was approved by Life science
committee of Japan Advanced Institute of Science and
Technology.
Results and discussion
Extraction of important genes regulated by alternative
splicing
Previously, we obtained 262 candidate exons (236 genes)
that were differentially alternatively spliced during neur-
onal differentiation of P19 cells [12]. Validation by RT-PCR
indicated that the expressions of 87% of them actually
changed; therefore, we used the 262 exons as good ex-
ample for subsequent analysis (Figure 1). This was
performed in a mouse Exon Array; therefore, intact infor-
mation of these exons was provided as probeset sequences
(probeset seqs). These probeset seqs were analyzed in a
genome viewer; human blat analysis. According to anno-
tated Refseqs, mRNAs or ESTs, the 262 alternative exons
were analyzed and the two entire amino acid sequences
that the alternative exon candidate joined or excised in its
transcripts were determined (Figure 1, Additional file 2:
Table S2). Occasionally, several Refseqs were annotated at
the genome locus. In these cases, we selected the most
plausible and representative transcript that involved in the
alternative exon. Although 81 probeset seqs were located
in the untranslated regions (UTRs), 52 probeset seqs in-
dicated exons that contained protein-coding sequences
Figure 1 Flow chart of the comprehensive informatics approach to alternative splicing. 262 differentially alternatively spliced (DAS) exons
obtained by Exon Array analysis were tested because it was suggested that approximately 87% of these DAS exons were changed during neuronal
differentiation of P19 cells [12]. The exons were determined and their transcripts with/without DAS exons were collected and translated. A conserved
domain search suggested that the functional domains could be changed in 128 pairs via alternative splicing. Moreover, comparison of gene
annotations and their domain descriptions suggested that alternative splicing in 49 genes affected their critical functional domain. Pathway analysis
suggested that the EGFR/mTOR signaling pathway could be the most affected molecular network.
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non-coding UTR exons could cause changes in the amino
acid sequence. Altogether, 241 entire transcript sequences
producing changes of amino acid sequence by includ-
ing and excluding the alternative exon were identified
(Figures 1 and 2A, Additional file 2: Table S2).
To clarify the effects on functional domains of the
alternative exons, we performed a conserved domain
search at NCBI. Among 241 variable coding regions, 128
might cause changes to the annotated domains (Figures 1
and 2A). The others were suggested to affect N-terminal
regions, C-terminal regions and linker region (inter-do-
mains) (Figure 2A). In the case of alternative promoters or
polyadenylation, their upstream or downstream exons
could be excluded from its transcript, respectively. There-
fore, some alternative exons are responsible for longer
amino acid sequences and affect large parts of the amino
acid sequence. These case are shown in the upper right
area of Figure 2B and these drastic changes of amino acid
sequences mostly caused functional domain changes (blue
dots). In addition, many alternative splicings changed <
100 amino acids and < 20% of the full-length protein, as
shown in lower left area of Figure 2B. Some of them also
produced alterations in functional protein domains
(Figure 2B).
For the 128 regions that changing their domains, we
extracted the descriptions of their domains from the
NCBI conserved domain search. We also performedGene Ontology (GO) analysis of the corresponding 128
genes. We compared the domain descriptions with the
GO terms, and found 49 genes (54 probeset seqs, inclu-
ding five probeset seqs that indicated the same exons
and/or domains) that had words in common, not including
conjunctions and prepositions (Figures 1 and 2A). Thus,
the critically important molecular functions of 49 genes
could be affected or regulated by their differentially alter-
natively spliced exons.
Pathway analysis based on the domain change
To find molecular networks or pathways that involved the
differentially alternatively spliced exons, we subjected
the 49 genes to pathway analysis. As a result, we identi-
fied the EGFR/mTOR signaling pathway as the most
significantly linked network by these alternative exons
(Figures 1 and 3). There were seven alternative splicing
events in this pathway. For example, the alternative
exon of Egfr (epidermal growth factor receptor) suggested
that the extracellular protein isoform was expressed via al-
ternative polyadenylation located in an adjacent upstream
exon that encoded the transmembrane domain [35]. Al-
though the expected extracellular isoform of Egfr is inter-
esting, the distinct functions of this isoform are unclear.
The alternative exon of mTor (mammalian target of rapa-
mycin) is part of the N-terminal predicted short protein
isoform predictively, which has been reported to be regu-
lated by an alternative splicing regulator, SAM68, during
Figure 2 Graphical representations of the relationship of probesets sequences to protein domains. (A) Comprehensively obtained signals
were originally annotated as probeset sequences. All probeset sequences of the 262 DAS exons were manually examined to determine whether
these sequences were protein coding regions or untranslated regions (UTR). Each alternative exon sequence was determined based on the annotated
Refseq, mRNAs and ESTs in genome viewer. Among the 262 determined exon sequences, approximately half of them are protein-coding exons
(3rd bar, blue). Approximately 40% of the exons sequences contained both protein coding region and UTR (3rd bar, green). Only 26 exons comprised
UTR without coding region (3rd bar, violet). Ultimately, 241 DAS exons were predicted to affect amino acid sequences (protein sequences). Moreover,
128 DAS exons were predicted to affect protein domain(s). Finally, 49 genes (54 probeset seqs, including five probeset seqs that indicated the same
exons and/or domains) were extracted whose representative function was predicted to be affected by alternative splicing. Grey color indicates the
not-determined exons. (B) The relationship between length of the altered protein sequences and domains are shown. A dot indicates an exon that
changed a protein domain(s). A triangle indicates an exon that did not change a domain. A cross indicates an exon that did not change the protein
sequence. DAS exons that are regulated by alternative promoters or polyadenylation may affect longer amino acid sequences with a high occupancy
rate, and are likely to more frequently affect protein domain(s), as observed in upper-right area of the panel. Meanwhile, it is predicted that some short
alternative exons also are able to change protein domains.
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nonsense mediated mRNA decay [36]. Meanwhile, Tsc2
(tuberous sclerosis 2) was in the original 262 candidate
exons but was eliminated from the 49 exons (Figure 3)
[12] because the region affected by the alternative exon
did not encode a functional domain.
Generally, differentially expressed genes affect bio-
logical phenomena. Thus, we also checked and extracted
the differentially expressed genes associated with the
EGFR/mTOR pathway, and assessed with their increasedor decreased expression (Figure 3) [12]. Additionally, it
was reported that protein expression of p53 could in-
crease during the neuronal differentiation of P19 cells
[37]. Including gene expressions and exons expression,
various transcripts were observed to have altered in this
pathway. However, it is speculated that upregulation
of Egfr gene expression increases the potency of its sig-
nal, while increased expression of its alternative exon
interferes with the signal via its imperfect extracellular
isoform.
Figure 3 Pathway analysis of 49 genes whose functional domains were changed by DAS exons. The EGFR/mTOR signaling pathway was
analyzed using 49 genes, where the functionalities of the changed domains were related to gene annotations. Thus, representative functions of
these genes may be regulated by alternative splicing events. Seven of them were shown with larger fonts with an inner color. The lines indicate
the intermolecular relationships. Medium fonts indicate differentially expressed genes suggested by a previous analysis [12]. Outer colors indicate
the elevation or reduction of their expressions. Smaller fonts indicate closely related upstream or downstream proteins. Blue or red indicate
successfully validated gain of function and elevation of expression or loss of function and reduction of expression, respectively. Success of the
validation by semi-quantitative RT-PCR was determined by an Fc value > 1.5 between undifferentiated P19 cells (day 0) and the cells at the neuronal
stage (day 7) (see also Figure 4). Light blue or orange colors indicate unsuccessful validation, even though these genes were suggested by a previous
microarray experiment. The violet inner color of Kitlg indicates that its domains were suggested to change but the gain or loss of function was difficult
to determine. Tsc2 was not one of the extracted 49 genes, but was one of 262 DAS exon genes. Indeed, its alternative isoforms have no difference in
their functional protein domains. Additionally, the transcript of p53 (TP53) was not listed as a differentially expressed gene; however, its protein level
was likely to be upregulated, as described in a previous report [37].
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pathway
Speculations based on gene expressions or exon expres-
sions may contradict each other. We suspected that
some comprehensive deposited data include partial or
uncertain information; we confirmed experimentally the
gene and exon expressions during neuronal differenti-
ation of P19 cells. First, we examined the expression ofalternatively spliced exons of Egfr using semi-quantitative
RT-PCR. The proportions of the transcript that encodes
extracellular isoform and full-length products changed
from about 1.5:8.5 to 4:6 during neuronal differentiation
of P19 cells (Figure 4). This was suggested by the
splicing index value (SI) in our previous study [12]. The
loss of domain type, such as an extracellular isoform,
increased; therefore, we marked EGFR the inner red
Figure 4 Validation of exon and gene expressions in the EGFR/mTOR pathway. (A) Schematic representation of alternative splicing in this
pathway. Exons indicated by probeset seqs are shown in red and additional exons that predict complex alternative splicing are shown in violet.
The mountain lines indicate the splicing patterns. (B) Gel images showing semi-quantitative RT-PCR performed using undifferentiated P19 cells
(Day 0), P19 cells at the neuronal cell stage (Day 7), and P19 cells at the early glial cell stage (Day 10). Each isoform of a transcript is indicated on
the right side. (C) Graphical representations of total gene expressions or the proportional changes of alternatively spliced products are shown on
the right axis using black lines or on the left axis using colored columns, respectively. After densitometric analyses, the highest amount of total
gene expression among three time points was considered as 1.0. Relative amounts of isoforms in total transcripts at each time point were considered
as 100%. Error bars indicate the standard error.
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extracellular isoform’s functionality compared with the
full-length product; therefore, it is difficult to determine
the functional changes induced in these isoforms. In
addition, the amounts of extracellular and full-lengthtype transcripts increased by approximately 6.8-fold and
1.7-fold, respectively (Figure 4). This change also corre-
lated with the change that was suggested by fold change
(FC) in neuronal gene expression in a previous compre-
hensive analysis [12]. We indicated increased gene-
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Figure 3.
In the case of another key factor in this network, the
SI value suggested that the N-terminal short isoform-
encoding transcript of mTor increased during neuronal
differentiation, and the FC value suggested that expres-
sion of the gene did not increase [12]. Actually, the rela-
tive amounts of N-terminal isoform products did
increase and the amount of total transcripts from the
mTor gene did not remarkably change during differenti-
ation (Figure 4). We indicated the increased loss of do-
main type, such as N-terminal short isoform of mTor,
with the inner red color in Figure 3. Although the func-
tion of the mTor N-terminal isoform is unclear during
differentiation, its transcript is degraded during adipo-
genesis [36]. Perhaps a truncated isoform that loses a
functional protein domain loses its function. As men-
tioned above, mTOR signaling promotes cell prolifera-
tion [24,38], and the N-terminal isoform lacks certain
domains present in the full-length protein. Cell differen-
tiation and cell proliferation are generally contrary phe-
nomena. Therefore, this N-terminal alternative spliced
isoform of mTor may be important for the neuronal dif-
ferentiation of P19 cells.
Although extracellular isoform of Egfr may negatively
affect this pathway, similar to the mTor N-terminal iso-
form, the full-length type Egfr transcripts increased.
Therefore, we tested the expressions of genes and their
exons that exist between EGFR and mTOR in the path-
way and that were suggested to change by their SI and
FC values. Typically, the Akt1 (RAC-alpha serine/threo-
nine-protein kinase) transcript increased 7-fold during
neuronal differentiation (Figure 4). The change of Akt1
alternative isoforms was not suggested by its SI value.
The decrease of gene expression of Tsc1 was suggested
by its FC and was observed to change slightly during
differentiation (Figure 4). Although the suggested
change of Tsc2 was validated, the effect of its alternative
splicing is unclear. Another suggested downstream
gene, Shc1 (SHC-transforming protein 1), was validated
and decreased during differentiation (Figure 4). Thus,
gene expressions of Egfr and Akt1 increased, but the ex-
pressions of other genes in this pathway did not. Besides
mTor or Tscs, various target proteins of Akt1 have been
identified [reviewed in 39]. We speculated that other
target proteins may be dramatically upregulated by en-
hanced Akt1 potency, according to their gene expres-
sions. In the case of mTor, its alternative N-terminal
product may slightly negatively modulate the enhanced
input signals.
Meanwhile, some upstream genes of the EGFR path-
way, such as Hbegf (Heparin-binding EGF-like growth
factor) and Arhgef12 (Rho guanine nucleotide exchange
factor 12) increased (Figures 3 and 4). The alternativeisoform of Arap1 (ArfGAP with RhoGAP domain, anky-
rin repeat and PH domain 1) was not detected; however,
the expression of its full-length product decreased dur-
ing differentiation (Figure 4). In the case of Ep400 (E1A
binding protein p400), its expression increased and the
alternatively spliced product may positively affect EGFR
pathway according to its changed domain. Additionally,
changes in indirectly related genes, such as Kitlg (KIT
Ligand) and Cdkn2a (cyclin-dependent kinase inhibitor
2A) were also validated their gene- and exon- expres-
sions during differentiation (Figures 3 and 4). However,
the functional change caused by the domain modifica-
tion by alternative splicing of Kitlg was unclear. It was
difficult to determine the effects on EGFR signaling
because upstream genes showed positive and negative
changes.
Time-course analysis of gene and exon expressions of Egfr
Autonomous regulation represents one possible explan-
ation of the contradictory expressions of the Egfr gene and
exons. For example, increased gene expression indirectly
affects its alternative splicing to repress gene function. To
test this hypothesis, we prepared a series of cDNAs from
the undifferentiated stage to the glial cell stage of P19
cells. We then examined the most changed time points of
Egfr gene or exon expression. The relative amount of the
extracellular Egfr isoform increased in the day 1 sample
during neural induction by retinoic acid (RA) under aggre-
gation culture (Figure 5). Similar fast responses by alterna-
tive splicing have been observed in other genes during
differentiation [40,41]. The previously reported genes were
also regulated by RA and/or cell aggregation. At this time
point, the total amount of Egfr transcript showed little
change (Figure 5). The proportion of the extracellular iso-
form then decreased, before rising again from day 4 to day
9: from neural induction to the neuronal cell stage of P19
cells (Figure 5). On the other hand, increased Egfr gene ex-
pression was observed from day 3 to day 8 (Figure 5). In
other words, the elevation of Egfr gene expression was
started 1 day before the proportional increase of its extra-
cellular isoform and stopped 1 day before the isoform
began to decrease again. Similarly, we tested mTor using a
series of cDNAs. Its N-terminal isoform was elevated dur-
ing the neural induction and differentiation stages, which
was completely different from Egfr. Although the expres-
sion of the Egfr gene and its alternative isoforms expres-
sions fitted with the autonomous regulation hypothesis
and may rebalance their functions, we lack proof of the
hypothesis. This should be addressed in our future work.
Conclusions
Changes in alternative exons affect protein functions via
alterations of amino acid sequences and functional
domains. Our method extracted alterations of
Figure 5 Time-course experiments of alternatively spliced Egfr and mTor transcripts. Detailed expression analyses of gene and exon
expressions of Egfr and mTor are shown in the gel image. Using a series of cDNAs; from Day 0–12, exon expressions were examined. At the same time,
gene expressions were quantified by the densitometric analyses of total transcripts. Graphical representations of gene or exon expressions are shown
in the upper panel and lower panel, respectively. Error bars indicate the standard errors.
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cing events. We found that the EGFR/mTOR signaling
pathway was the most affected pathway. The import-
ance of mTOR in neuronal differentiation has been re-
ported, suggesting that this in silico extraction of
alternative splicing network is a useful strategy. This
strategy for the analysis of alternative splicing should be
automated. The experimental validations of exon andgene expression by RT-PCR suggested that the increase
in the products of genes such as Egfr and Akt1 might in-
crease the signal through the pathway during neuronal
differentiation of P19 cells, meanwhile the alternative
splicing events in mTor might control this pathway re-
pressively. We speculate that our method will contrib-
ute to future studies of new molecular networks of
alternative splicing regulation.
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Additional file 1: Table S1. List of primer sequences and PCR
conditions.
Additional file 2: Table S2. Results of the analyses in 262 DAS exons.
Using filter conditions of the last column, 49 gene with 54 probesets are
listed.
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